GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Announce the DEA has Rescheduled EPIDIOLEX (cannabidiol) Oral Solution to Schedule V
GW Pharmaceuticals Announces Preliminary Results of Phase 2a Study for its Pipeline Compound GWP42006
Premier American Uranium Reports Results Following Annual General and Special Meeting of Shareholders
Nuvau Winter Drilling at Thundermine Returns 5.28 g/t Au over 6.1 m, Including 7.22 g/t Au over 3.1 m
